Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma

Inclusion criteria

* Diagnosis of multiple myeloma (MM) requiring systemic therapy
* Age greater than or equal to (\>=) 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Life expectancy greater than (\>) 3 months
* Relapsed from or refractory to two or more different prior therapies
* Signed Informed consent

Exclusion criteria

* Plasma cell leukemia defined as a plasma cell count \> 2000/millimeter\^3 (mm\^3)
* Known amyloidosis
* Participants who previously have received an allogeneic stem cell transplant
* Sensory or motor neuropathy of \>= grade 3
* Past or current malignancy
* Chronic or ongoing active infectious disease
* Clinically significant cardiac disease
* Significant concurrent, uncontrolled medical condition including, but not limited to, renal (except related to MM), hepatic, hematological except MM, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease
* A baseline QT interval as corrected by Fridericia's formula \> 470 millisecond (msec) for female participants or \> 450 msec for male participants or a complete left bundle branch block (defined as a QRS interval \>= 120 msec in left bundle branch block form)
* Hypokalemia
* Clinical signs of meningeal involvement of MM
* Known severe chronic obstructive pulmonary disease or asthma defined as forced expiratory volume in 1 second (FEV1) less than (\<) 60 percentage (%) of expected
* History of significant cerebrovascular disease
* Known Human Immunodeficiency Virus seropositivity
* Positive serology for hepatitis B
* Screening laboratory values
* Concomitant corticosteroid
* Other chemotherapy that is or may be active against myeloma within 3 weeks prior to Visit 2 (Part 1) or the first dose of daratumumab (Part 2). However, corticosteroid for myeloma (less than a 4-day course) could be administered within 1 week before Visit 2 (Part 1) or the first dose of daratumumab (Part 2)
* Known hypersensitivity to components of the investigational product or severe allergic or anaphylactic reactions to humanized products
* Participants who have received treatment with any nonmarket drug substance within 4 weeks before the first dose of daratumumab
* Current participation in any other interventional clinical trial
* Participants known or suspected of not being able to comply with a trial protocol (example, due to alcoholism, drug dependency, or psychological disorder)
* Breastfeeding women or women with a positive pregnancy test at Screening
* Women of childbearing potential not willing to use adequate contraception, defined as hormonal birth control or intrauterine device, during the trial and for 1 year after the last dose of daratumumab. For participants in the United States, the use of a double-barrier method is also considered adequate